274 results on '"Van Assche G"'
Search Results
2. State-of-the-Art Lecture: The changing face of inflammatory bowel disease over recent decades
3. Water permeation in coatings
4. Prilling of API/fatty acid suspensions: Screening of additives for drug release modification
5. DOP83 Intestinal fibrosis in Crohn’s disease patients is marked by up-regulation of innate immune cells and mucosal B cells
6. OP37 Fibrogenesis in chronic DSS colitis is driven by an innate lymphoid cell-independent innate immune response
7. P219 Disease-specific avoidance is a predictor for fatigue in inflammatory bowel disease patients
8. Use of serology and genetics to differentiate inflammatory bowel disease phenotypes
9. Prilling of API/fatty acid suspensions: Processability and characterisation
10. Biologicals: old and new ones
11. Cx601 (darvadstrocel) for the treatment of perianal fistulizing Crohn’s disease
12. Efficacy and Safety of Ustekinumab as Maintenance Therapy in Ulcerative Colitis: Week 44 Results from UNIFI
13. Efficacy in Biologic Failure and Nonbiologic-Failure Populations in a Phase 3 Study of Ustekinumab in Moderate-Severe Ulcerative Colitis: UNIFI
14. Sustained Remission in Patients with Moderate to Severe Ulcerative Colitis: Results from the Phase 3 UNIFI Maintenance Study
15. CAPNOGRAPHY DURING ENDOSCOPY – A VALUE-BASED HEALTHCARE PILOT IN A HIGH-VOLUME GASTROENTEROLOGY PRACTICE
16. DOP38 A vedolizumab specific four-gene colonic signature accurately predicting future endoscopic remission in patients with inflammatory bowel disease
17. P827 Up-regulation of IL17-related pathways in affected colon from ulcerative colitis compared with Crohn’s disease
18. DOP70 An integrated multi-omics biomarker predicting endoscopic response in ustekinumab treated patients with Crohn's disease
19. OP37 Efficacy and safety of ustekinumab as maintenance therapy in ulcerative colitis: Week 44 results from UNIFI
20. P311 Pharmacokinetics and exposure–response relationships of intravenously administered ustekinumab during induction treatment in patients with ulcerative colitis: Results from the UNIFI induction study
21. P312 Efficacy in biologic failure and non-biologic-failure populations in a Phase 3 study of ustekinumab in moderate–severe ulcerative colitis: UNIFI
22. P820 Molecular changes in non-inflamed terminal ileum in patients with ulcerative colitis
23. DOP26 Biological therapy increases NCR+ ILC3 levels in IBD patients
24. P032 Hepatocyte growth factor and MET in ulcerative colitis, novel drug targets impairing neutrophil recruitment?
25. DOP54 Efficacy and safety of ustekinumab through Week 16 in patients with moderate-to-severe ulcerative colitis randomised to ustekinumab: results from the UNIFI induction trial
26. P821 Distinct and common gene expression profiles between inflamed ileum and colon of newly diagnosed CD patients
27. P385 TREM1, the first anti-TNF specific biomarker guiding therapeutic decision
28. P001 Multi-omic data integration assisted identification of molecular features contributing to disease heterogeneity in Crohn's disease
29. P542 Efficacy and safety of biological therapies in chronic antibiotic-refractory pouchitis: a retrospective single-centre experience
30. DOP37 Vedolizumab-induced endoscopic remission in anti-TNF exposed and anti-TNF naïve IBD patients: a large single-centre experience
31. DOP47 Sustained remission in patients with moderate to severe ulcerative colitis: Results from the Phase 3 UNIFI maintenance study
32. P155 Adherence to quality indicators among patients with inflammatory bowel disease: an international comparative analysis
33. Room-temperature versus heating-mediated healing of a Diels-Alder crosslinked polymer network
34. An expert consensus to standardise definitions, diagnosis and treatment targets for anti‐fibrotic stricture therapies in Crohn's disease
35. IMPACT OF ENDOSCOPY SYSTEM, HIGH-DEFINITION AND VIRTUAL CHROMOENDOSCOPY IN DAILY ROUTINE COLONOSCOPY
36. Outcome of restorative proctocolectomy with an ileo-anal pouch for ulcerative colitis: effect of changes in clinical practice
37. P548 Limited clinical value in assessing the distribution of endoscopic disease activity in patients with ulcerative colitis
38. P042 Decreased leukocyte trafficking may contribute to vedolizumab refractory disease after anti-TNF exposure in patients with ulcerative colitis
39. OP007 Detection of mucosal healing with a serum marker panel in adalimumab-treated patients with ulcerative colitis
40. P035 Serum markers predict outcome to ustekinumab in patients with refractory Crohn’s disease and provide insides in the mechanism of action
41. P330 A prospective trial to evaluate the feasibility of a mobile app in patients with inflammatory bowel disease under maintenance therapy
42. P052 Protein biomarkers identify subclinical inflammation patterns in first-degree relatives of patients with inflammatory bowel disease
43. P661 Endoscopy-based therapeutic management in postoperative recurrent Crohn’s disease: Results of a multi-centre retrospective study
44. OP003 Temporal changes in immune pathways with consecutive biological therapies as measured by serum proteomics
45. P010 Serum proteomic profiling in Crohn’s disease patients undergoing ileocolonic resection reveals discriminative inflammatory markers for endoscopic recurrence
46. P431 Golimumab dried blood spot analysis (GOUDA): A prospective trial to validate golimumab concentration analysis using the dried blood spot methodology
47. P273 Efficacy and safety of upadacitinib maintenance treatment for moderate to severe Crohn’s disease: Results from the CELEST study
48. P642 Adaptive dosing during infliximab induction therapy can improve mucosal healing rates in patients with ulcerative colitis
49. P005 A multi-marker serum test to assess the presence of ulcerations in infliximab treated patients with Crohn’s disease
50. P527 Low adalimumab serum levels at Week 4 provoke immunogenicity and influence therapy outcome in anti-TNF naïve Crohn’s disease patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.